SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

ICICI Securities Recommends Buying Dr Reddy’s, Sets Rs 1,430 Target

ICICI Securities cited new US launches and product mix, saying Dr Reddy’s Q2FY27 EBITDA and PAT were about 32% and 26% ahead of its expectations. US sales rose 9.5% quarter over quarter to USD 258 million, supported by sugammadex and bosutnib launches.

DRREDDY

Related stories